	US 12,419,961 B2
	Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity
Hojun Kim, Seoul (KR); and Geun-Woo Jin, Seoul (KR)
Assigned to CNPharm Co., Ltd., Seoul (KR)
Filed by CNPharm Co., Ltd., Seoul (KR)
Filed on Apr. 13, 2022, as Appl. No. 17/719,718.
Application 17/719,718 is a continuation in part of application No. 17/320,592, filed on May 14, 2021, abandoned.
Claims priority of provisional application 63/174,175, filed on Apr. 13, 2021.
Prior Publication US 2022/0323589 A1, Oct. 13, 2022
Int. Cl. A61K 47/54 (2017.01); C07D 407/12 (2006.01)

CPC A61K 47/545 (2017.08) [C07D 407/12 (2013.01)]

13 Claims

1. A compound useful as an anti-cancer drug having the following formula: